Vinergy Capital Evolving to MedBright AI Investments with
Name Change
An Emerging Markets Sponsored
Commentary
ORLANDO, Fla., Nov. 21, 2023 -- InvestorsHub NewsWire -- In
previous issues of the Emerging
Markets Report, we've covered what we believe will be
transformative for the Issuer discussed below via the adoption of
Artificial Intelligence in Health Care. It's clear to us that AI
driven Health Care will be smarter, more effective and more
compassionate as it provides better health care outcomes to more
and more patients.
And so it makes sense for MedBright AI Investments
Inc. (OTCQB: MBAIF, CSE: MBAI) (the "Company" or "MedBright
AI") formally known as Vinergy Capital Inc. to align
its brand with this opportunity, all while developing and refining
a portfolio of A.I. health care technologies and acquiring more
consultants and human capital under its proverbial roof. Consistent
with this plan, the Company decided that a name change to MedBright
AI Investments is in order, which is trading under the ticker
"MBAIF" on the OTCQB, and is the new name and
ticker for the Company formerly known as Vinergy Capital.
As we see it, the Company has gone through an evolution over the
past few months, rapidly expanding and improving in the race to
seize market share in the highly lucrative Health Care/A.I.
opportunity. The name change to MedBright AI reflects the Company's
current business purposes and more accurately identifies its
brand.
The foray into A.I. driven health care is well-founded. As we
previously reported a recent research report by a firm completely
unrelated to Vinergy projects that the "Worldwide Artificial
Intelligence in Healthcare Market Size is expected to reach USD
280.77 Billion by 2032." (source
link.)
Since we last published that report MedBright AI (formally
Vinergy Capital) has been busy.
In October, the Company
announced that it had added another A.I. expert to its investment
committee, with Trevor Vieweg, a co-founder of Limmi, an
AI platform focused on powering the world's most complex healthcare
data analytics systems. Vieweg has an outstanding resume including
an important stint as Head of Product Development for a big NASDAQ
outfit.
When we see hires like this, they can be a big deal, as the
hiring very likely brings the new team member's contacts and
relationships as well as their expertise. And of course, when an
industry pro jumps into a deal it generally sends a signal that a
better mind than the layman saw something and wants to be
involved.
On top of this was a powerful
announcement that the Company had made another significant
investment in the aforementioned Limmi, a FDA and HIPPA
compliant Artificial Intelligence Platform.
Limmi's tech is described as "a cutting-edge data and analysis
artificial intelligence platform for life sciences applications
that is both FDA and HIPAA compliant. Through machine learning
models, Limmi transforms life science data into actionable insights
to transform drug discovery and early disease detection."
Read that last line one more time… "Limmi transforms life
science data into actionable insights to transform drug discovery
and early disease detection."
Health Care Artificial Intelligence. Transforming Drug
Discovery. Identifying diseases earlier.
The future for A.I. in improving patient outcomes is
compelling.
Probably just about the right time to have a name that meets the
moment.
About The Emerging Markets Report:
The Emerging Markets Report is owned and operated
by Emerging Markets Consulting (EMC), a syndicate of investor
relations consultants representing decades of experience. Our
network consists of stockbrokers, investment bankers, fund
managers, and institutions that actively seek opportunities in the
micro and small-cap equity markets.
For more informative reports such as this, please sign up
at:
https://emergingmarketsconsulting.com/
Must
Read OTC Markets/SEC policy on stock promotion and investor
protection
Section
17(b) of the Securities Act of 1933 requires that any person that
uses the mails to publish, give publicity to, or circulate any
publication or communication that describes a security in return
for consideration received or to be received directly or indirectly
from an issuer, underwriter, or dealer, must fully disclose the
type of consideration (i.e. cash, free trading stock, restricted
stock, stock options, stock warrants) and the specific amount of
the consideration. In connection therewith, EMC has received the
following compensation and/or has an agreement to receive in the
future certain compensation, as described below.
EMC has been
paid $90,000 by MedBright AI Investments Inc. EMC does not
independently verify any of the content linked-to from this
editorial. | Please read our full
disclaimer.
Emerging Markets Consulting, LLC
Florida Office
390 N Orange Ave. Suite 2300
Orlando, FL 32801
E-mail: jamespainter@emergingmarketsllc.com
Web: https://emergingmarketsconsulting.com/